(Q36744614)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

metabolic dysfunction–associated steatotic liver disease

26 December 2019

main subject

steatohepatitis

0 references

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

non-alcoholic steatohepatitis

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Antonio Grieco

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

3

Giovanni Gasbarrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Alessandra Forgione

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

1 reference

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

114-125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Liver fibrosis in overweight patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Activation of hepatic stellate cells--a key issue in liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Steatohepatitis: a tale of two "hits"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Apolipoprotein synthesis in nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

NASH: a mitochondrial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Non-alcoholic fatty liver disease: current concepts and management strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Evaluation of liver fibrosis: a concise review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Review article: the evolving role of liver biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Sampling variability of liver fibrosis in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

The utility of radiological imaging in nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Fibrosis in chronic liver diseases: diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Long term prognosis of fatty liver: risk of chronic liver disease and death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Non-alcoholic steatohepatitis: review of a growing medical problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

NASH: a hidden and silent fibroser finally revealed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Cytokines and fibrogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Molecular regulation of hepatic fibrogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Molecular mechanisms of liver fibrogenesis--a homage to the role of activated fat-storing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Transforming growth factor-beta gene expression in normal and fibrotic rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic fibrosis as wound repair: a progress report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Serum YKL-40 is increased in patients with hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Serum markers detect the presence of liver fibrosis: a cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Candidate gene case-control association studies: advantages and potential pitfalls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

The potential role of genes in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

High density synthetic oligonucleotide arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Association of differentially expressed genes with activation of mouse hepatic stellate cells by high-density cDNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2006.11.011

10.1016/J.TRSL.2006.11.011

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320797%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference